Ambrosin
Ambrosin is an orally active NF-κβ and BACE1 inhibitor. Ambrosin reduces pro-inflammatory and nitrosative mediators, increases PPARγ levels, inhibits apoptosis (Apoptosis), enhances autophagy (Autophagy), and ameliorates oxidative stress. Ambrosin reduces Amyloid plaque deposition. Ambrosin improves lipopolysaccharide-induced memory impairment and colonic histopathological changes. Ambrosin can be used in research related to Alzheimer's disease and colitis.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 509-93-3
- 分子式: C15H18O3
- 分子量:246.31
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
|
PPAR-γ |
BACE1 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | GI50 |
1.8 μM
Compound: 1
|
The compound was evaluated for cytotoxicity against colon cancer cell line HCT116
The compound was evaluated for cytotoxicity against colon cancer cell line HCT116
|
[PMID: 7650694] |
| KB | ED50 |
0.45 μg/mL
Compound: 12. Ambrosin
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 17336532] |
| KB | ED50 |
1.83 μM
Compound: ambrosin
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 18329753] |
| LOX IMVI | GI50 |
2.2 μM
Compound: 1
|
The compound was evaluated for cytotoxicity against melanoma cell line LOX-IMVI
The compound was evaluated for cytotoxicity against melanoma cell line LOX-IMVI
|
[PMID: 7650694] |
| LOX IMVI | GI50 |
2.2 μM
Compound: 6
|
Antiproliferative activity against human LOXIMVI cells
Antiproliferative activity against human LOXIMVI cells
|
10.1039/C2MD20172K |
| MCF7 | GI50 |
3.9 μM
Compound: 1
|
The compound was evaluated for cytotoxicity against breast cancer cell line MCF-7
The compound was evaluated for cytotoxicity against breast cancer cell line MCF-7
|
[PMID: 7650694] |
| MCF7 | GI50 |
3.9 μM
Compound: 6
|
Antiproliferative activity against human MCF7 cells
Antiproliferative activity against human MCF7 cells
|
10.1039/C2MD20172K |
| NCI-H522 | GI50 |
1 μM
Compound: 1
|
The compound was evaluated for cytotoxicity against lung cancer cell line NCI-H522
The compound was evaluated for cytotoxicity against lung cancer cell line NCI-H522
|
[PMID: 7650694] |
| NCI-H522 | GI50 |
1 μM
Compound: 6
|
Antiproliferative activity against human NCI-H522 cells
Antiproliferative activity against human NCI-H522 cells
|
10.1039/C2MD20172K |
| OVCAR-5 | GI50 |
4.9 μM
Compound: 1
|
The compound was evaluated for cytotoxicity against ovarian cancer cell line OVCAR-5
The compound was evaluated for cytotoxicity against ovarian cancer cell line OVCAR-5
|
[PMID: 7650694] |
| PC-3 | GI50 |
4.5 μM
Compound: 1
|
The compound was evaluated for cytotoxicity against prostate cancer cell line PC-3
The compound was evaluated for cytotoxicity against prostate cancer cell line PC-3
|
[PMID: 7650694] |
| SF-539 | GI50 |
2.9 μM
Compound: 1
|
The compound was evaluated for cytotoxicity against CNS cancer cell line CNS SF-539
The compound was evaluated for cytotoxicity against CNS cancer cell line CNS SF-539
|
[PMID: 7650694] |
| SN12C | GI50 |
3.4 μM
Compound: 1
|
The compound was evaluated for cytotoxicity against renal cancer cell line SN12C
The compound was evaluated for cytotoxicity against renal cancer cell line SN12C
|
[PMID: 7650694] |
Ambrosin exhibits predicted high gastrointestinal absorption, favorable lipid solubility, and robust BBB permeability, indicating superior pharmacokinetic properties for central nervous system targeting compared to curcumin[1].
Ambrosin binds to the NF-κβp65-DNA complex via hydrogen bonding and hydrophobic interactions, indicating reversible inhibition of NF-κβp65 activation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Ambrosin (10 mg/kg; p.o.) significantly mitigates DSS-induced colitis in male BALB/c mice by restoring antioxidant balance, suppressing pro-inflammatory signaling pathways, enhancing autophagy, and inhibiting apoptosis[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Albino mice (mature male, 120-130 g, LPS-induced Alzheimer's disease model)[1]
-
Dosage:5 mg/kg; 10 mg/kg
-
Administration:i.p.; daily; 7 days
-
Result:Reduced mean escape latency time on days 3 and 4 to levels similar to the normal group (significantly lower than LPS control).
Increased mean time spent in the target quadrant to 25.59 sec (5 mg/kg) and 25.56 sec (10 mg/kg; LPS control: 12.20 sec; normal group: 23.38 sec).
Increased time spent exploring the novel object vs. the familiar object, and yielded significantly positive discrimination indices (significantly different from LPS control with negative index).
Reduced LPS-induced elevated NF-κβp65 transcript and protein levels in a dose-dependent manner, with 10 mg/kg reducing protein levels to values not significantly different from the normal group.
Significantly reduced LPS-induced elevated TNF-α, IL-1β, COX-2, and iNOS protein levels at 5 mg/kg; reduced these markers to levels similar to the normal group at 10 mg/kg.
Reduced LPS-induced elevated BACE1 protein levels in a dose-dependent manner.
Increased surviving hippocampal CA1 neurons to 35.66 per high power field (5 mg/kg; LPS control: 23.33) and 44.33 per high power field (10 mg/kg).
Reduced amyloid plaques to 2.50 per high power field (5 mg/kg; LPS control: 6.20) and 0.90 per high power field (10 mg/kg).
-
Animal Model:BALB/c (male, 16-26 g, DSS-induced colitis)[2]
-
Dosage:10 mg/kg
-
Administration:p.o.
-
Result:Significantly reduced disease activity index (DAI).
Restored colon length compared to DSS-only treated mice.
Increased colonic tissue levels of SIRT1, PPAR-γ, glutathione reductase, glutathione peroxidase, Nrf2, beclin-1, LC3-II, and Bcl-2.
Significantly decreased colonic tissue levels of ROS, iNOS, TLR-4, IL-1β, IL-6, TGF-β1, phospho-p38 MAPK, c-Fos, c-Jun, NLRP3 inflammasome, and caspase-8.
Attenuated DSS-induced histopathological damage, including reduced ulceration, crypt loss, and inflammatory cell infiltration.
Lowered histological disease score.
Reduced NF-κB (p65) nuclear immunostaining.
Improved electron microscopic features of colonic cells (nearly normal apical microvilli, mild cytoplasmic vacuolation, and mild mitochondrial swelling with partially destructed cristae).
化学情報
-
CAS 番号 509-93-3
-
分子量 246.31
-
分子式 C15H18O3
-
SMILES
C[C@]12[C@]3([C@](C(=C)C(=O)O3)(CC[C@H](C)[C@@]1(C=CC2=O)[H])[H])[H]
-
Structure Classification
-
Initial Source
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Khalil MNA, et al. Ambrosin, a potent NF-κβ inhibitor, ameliorates lipopolysaccharide induced memory impairment, comparison to curcumin. PloS one. 2019;14(7):e0219378. [Content Brief]
[2]. Kabel AM, et al. Perindopril/Ambrosin Combination Mitigates Dextran Sulfate Sodium-Induced Colitis in Mice: Crosstalk between Toll-Like Receptor 4, the Pro-Inflammatory Pathways, and SIRT1/PPAR-γ Signaling. Pharmaceuticals (Basel, Switzerland). 2022 May 13;15(5):600. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Ambrosin 関連分類
HY-N8912 関連分類
Powered by Bioz